Genflow's SIRT6-targeted gene therapy in aging dogs showed improved survival at three months post-treatment with no adverse events reported. The trial, enrolling 24 beagles over age 10, represents an early-stage assessment of whether genetic interventions can reverse hallmarks of aging in a mammalian model relevant to human longevity research.
Key Points
- Treated dogs demonstrated better survival rates than controls at three months
- No adverse events reported; biological age markers under review
- Six-month data will determine whether early improvements persist and guide next steps
Longevity Analysis
SIRT6 activation addresses a fundamental pathway in cellular regeneration and stress response—both critical to slowing aging processes. Early survival advantage in treated animals suggests the therapy may influence how cells manage energy production and respond to accumulated damage. The veterinary model provides a critical bridge to human application, allowing assessment of durability and safety in a living system with aging kinetics closer to human experience. Strong data at six months could validate whether targeted genetic interventions produce sustained benefits or if responses plateau, a distinction essential for designing effective human protocols.
Original published by LT Wire.